Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women ≥ 18 years old
Must have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy
Measurable disease by RECIST criteria
Must be able to undergo MRI evaluation
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Competent to sign and date an Institutional Review Board approved informed consent form
You may not be if
Presence of untreated or symptomatic primary central nervous system tumors or metastases
Unresolved hematological toxicities \> grade 1 with the exception of grade 2 lymphopenia and non-hematological toxicities \> grade 1, excluding alopecia and grade 2 neuropathy, from prior anti-cancer therapy
Myocardial infarction within 1 year before study day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function
History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study
Active peripheral vascular disease
History of bleeding diathesis
History of pulmonary hemorrhage or gross hemoptysis within 6 months before study
Known history of adrenal hemorrhage
Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C
Major surgery within 1 month before study
Prior treatment with any agent targeting the angiopoietin-Tie2 signaling pathway
Concurrent antitumor treatment, except Lupron for subjects with prostate cancer and selective estrogen receptor modulators (SERMS) for subjects with breast cancer, within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1
Known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing
Investigational agent within 30 days before study
Pregnant (eg, positive urine test) or breastfeeding
Subjects of childbearing potential, or subject who has a partner of childbearing potential, and is not using highly effective contraceptive precautions
Clareo Health | A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
